William Blair Downgrades Spark Therapeutics (ONCE) to Market Perform Following Takeout Bid by Roche
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
William Blair analyst Raju Prasad downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to Market Perform.
Shares of Spark Therapeutics closed at $113.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Las Vegas Sands (LVS) Downgraded to Hold at Jefferies on Limited Upside Potential
- BofA Securities Downgrades O'Reilly Automotive (ORLY) to Neutral
- UBS Downgrades Anglo American Plc. (AAL:LN) (NGLOY) to Sell
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesWilliam Blair
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!